JP2014520767A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520767A5
JP2014520767A5 JP2014517492A JP2014517492A JP2014520767A5 JP 2014520767 A5 JP2014520767 A5 JP 2014520767A5 JP 2014517492 A JP2014517492 A JP 2014517492A JP 2014517492 A JP2014517492 A JP 2014517492A JP 2014520767 A5 JP2014520767 A5 JP 2014520767A5
Authority
JP
Japan
Prior art keywords
group
atoms
hal
cyc
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520767A (ja
JP6116554B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/002469 external-priority patent/WO2013004332A1/en
Publication of JP2014520767A publication Critical patent/JP2014520767A/ja
Publication of JP2014520767A5 publication Critical patent/JP2014520767A5/ja
Application granted granted Critical
Publication of JP6116554B2 publication Critical patent/JP6116554B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517492A 2011-07-07 2012-06-11 がんの処置のための置換されたアザ複素環 Expired - Fee Related JP6116554B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161505376P 2011-07-07 2011-07-07
US61/505,376 2011-07-07
PCT/EP2012/002469 WO2013004332A1 (en) 2011-07-07 2012-06-11 Substituted azaheterocycles for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2014520767A JP2014520767A (ja) 2014-08-25
JP2014520767A5 true JP2014520767A5 (enExample) 2015-07-30
JP6116554B2 JP6116554B2 (ja) 2017-04-19

Family

ID=46354143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517492A Expired - Fee Related JP6116554B2 (ja) 2011-07-07 2012-06-11 がんの処置のための置換されたアザ複素環

Country Status (9)

Country Link
US (1) US9199962B2 (enExample)
EP (1) EP2729459B1 (enExample)
JP (1) JP6116554B2 (enExample)
CN (1) CN103649074B (enExample)
AU (1) AU2012280725B2 (enExample)
CA (1) CA2840883C (enExample)
ES (1) ES2698847T3 (enExample)
IL (1) IL230218A (enExample)
WO (1) WO2013004332A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
MX2015002310A (es) 2012-08-23 2015-06-05 Hoffmann La Roche Nuevas amidas de fenil-piridina/pirazina para el tratamiento de cancer.
HK1213798A1 (zh) 2012-10-15 2016-07-15 安吉奥斯医药品有限公司 治療性化合物和組合物
JP6412503B2 (ja) 2012-11-21 2018-10-24 ピーティーシー セラピューティクス, インコーポレイテッド 置換逆ピリミジンBmi−1阻害剤
JP2016504365A (ja) * 2012-12-28 2016-02-12 アメリカ合衆国 Usp1/uaf1デユビキチナーゼ複合体阻害剤及びその使用
US9120750B2 (en) 2013-03-07 2015-09-01 Northwestern University 2-Aminopyridine-based selective neuronal nitric oxide synthase inhibitors
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
AU2014287121B2 (en) 2013-07-11 2018-11-15 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CA2922657C (en) 2013-08-30 2022-04-12 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
PE20160608A1 (es) 2013-10-14 2016-07-08 Eisai Randd Man Co Ltd Compuestos de quinolina selectivamente sustituida
RU2671496C2 (ru) 2013-10-14 2018-11-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные 5-пиперидин-8-цианохинолина
EP3071553A4 (en) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
JP6564796B2 (ja) 2014-03-14 2019-08-21 アジオス ファーマシューティカルズ, インコーポレイテッド 治療活性化合物の医薬組成物
US10759791B2 (en) 2014-11-04 2020-09-01 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
US9951014B2 (en) 2014-11-04 2018-04-24 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
EP3362065B1 (en) 2015-10-15 2024-04-03 Les Laboratoires Servier Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia
LT3362066T (lt) 2015-10-15 2022-02-10 Les Laboratoires Servier Sas Kombinuota terapija, skirta piktybinių susirgimų gydymui
KR102628675B1 (ko) 2017-05-26 2024-01-25 캔써 리서치 테크놀로지 리미티드 벤즈이미다졸론 유래된 bcl6의 저해제
CN119330979A (zh) 2018-04-13 2025-01-21 癌症研究技术有限公司 作为bcl6抑制剂的化合物及其制备方法
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
BR112021002630A2 (pt) 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático
EP3892617B1 (en) 2018-12-07 2025-04-30 Unimatec Co., Ltd. Fluorinated pyrimidine compound and production method therefor
TW202132285A (zh) * 2019-11-13 2021-09-01 美商愛彼特生物製藥股份有限公司 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法
CN119504704A (zh) 2020-05-19 2025-02-25 优迈特株式会社 含氟嘧啶化合物和含氟嘧啶酮化合物
US12213973B2 (en) 2021-10-18 2025-02-04 Northwestern University Bacterial nitric oxide synthase inhibitors
WO2023085142A1 (ja) 2021-11-12 2023-05-19 ユニマテック株式会社 含フッ素ピリミジン化合物、有害菌類防除剤および含フッ素ピリミジン化合物の製造方法
JP2025515319A (ja) * 2022-04-29 2025-05-14 江▲蘇▼▲亞▼虹医▲薬▼科技股▲フン▼有限公司 ピリミジン化合物、それを調製するための方法、及びその薬学的使用
CN120202201A (zh) * 2022-11-04 2025-06-24 深圳晶泰科技有限公司 泛素特异性蛋白酶1的抑制剂及其应用
WO2025007777A1 (zh) * 2023-07-05 2025-01-09 江苏亚虹医药科技股份有限公司 嘧啶类化合物、其制备方法及其医药用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2114662T3 (es) * 1993-08-26 1998-06-01 Ono Pharmaceutical Co Derivados de la 4-aminopirimidina.
WO1996033972A1 (en) * 1995-04-28 1996-10-31 Glaxo Group Limited Methods for synthesizing diverse collections of pyridines, pyrimidines, 1,4-dihydro derivatives thereof, and piperidine derivatives
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
DE60136731D1 (de) * 2000-09-20 2009-01-08 Ortho Mcneil Pharm Inc Pyrazine derivate als tyrosin kinase modulatoren
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
WO2002047690A1 (en) * 2000-12-12 2002-06-20 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2002060492A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
CN1642422A (zh) * 2002-03-15 2005-07-20 西巴特殊化学品控股有限公司 4-氨基嘧啶及其在表面抗菌处理中的应用
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7459460B2 (en) * 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
EP1638955A2 (en) * 2003-07-02 2006-03-29 Vertex Pharmaceuticals Incorporated Pyrimidines useful as modulators of voltage-gated ion channels
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
MXPA06010900A (es) * 2004-03-26 2007-02-21 Methylgene Inc Inhibidores de histona desacetilasa.
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
CN101730703B (zh) * 2007-03-16 2012-12-26 中国人民解放军军事医学科学院放射与辐射医学研究所 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂
CA2681516A1 (en) 2007-03-22 2008-09-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of janus kinases
US20090048282A1 (en) * 2007-08-14 2009-02-19 Wyeth Pyrimidine sulfonamide analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009027736A2 (en) * 2007-08-27 2009-03-05 Astrazeneca Ab 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
WO2009039542A2 (en) 2007-09-24 2009-04-02 Fibrex Medical Research & Development Gmbh Methods of screening for compounds having anti- inflammatory activity and/or prevent / treat vascular leak
JP2010126496A (ja) * 2008-11-28 2010-06-10 Mitsubishi Tanabe Pharma Corp 複素環化合物
RU2535217C2 (ru) 2009-02-06 2014-12-10 Ниппон Синяку Ко., Лтд. Производные аминопиразина и лекарственные средства
WO2010126922A1 (en) 2009-04-30 2010-11-04 Glaxosmithkline Llc Benzimidazolecarboxamides as inhibitors of fak
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2013066839A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods

Similar Documents

Publication Publication Date Title
JP2014520767A5 (enExample)
JP2013501047A5 (enExample)
JP2012506389A5 (enExample)
JP2016503797A5 (enExample)
AR118341A2 (es) Mezclas fungicidas ternarias
JP2015536947A5 (enExample)
JP2012532899A5 (enExample)
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
JP2014508753A5 (enExample)
JP2012092103A5 (enExample)
RU2014129742A (ru) Производные бензолсульфонамида в качестве модуляторов rorc
UA112317C2 (uk) Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину
JP2014508811A5 (enExample)
JP2015522650A5 (enExample)
JP2012516871A5 (enExample)
JP2008509166A5 (enExample)
HRP20161103T1 (hr) Kemijski spojevi
JP2017501237A5 (enExample)
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
JP2013537203A5 (enExample)
JP2012508252A5 (enExample)
JP2015537008A5 (enExample)
JP2018533593A5 (enExample)
JP2015500842A5 (enExample)